<DOC>
<DOCNO>EP-0652013</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of bovine colostrum for the manufacture of a medicament for the treatment of liver malfunctions
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P116	C01B336	A61K3520	A61K3520	C01B300	A61P100	C07K1604	C07K1604	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C01B	A61K	A61K	C01B	A61P	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P1	C01B3	A61K35	A61K35	C01B3	A61P1	C07K16	C07K16	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to the use of bovine colostrum or colostrum formulations or immunoglobulin-containing fractions prepared therefrom as liver-protective preparation for the prevention and treatment of disturbances of liver function associated with liver disorders, in particular to avoid the consequences of these disorders, such as portal encephalopathy.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BIOTEST PHARMA GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
BIOTEST PHARMA GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
LISSNER REINHARD DR
</INVENTOR-NAME>
<INVENTOR-NAME>
MOELLER WOLFGANG DR
</INVENTOR-NAME>
<INVENTOR-NAME>
NITSCHE DIETRICH DR
</INVENTOR-NAME>
<INVENTOR-NAME>
LISSNER, REINHARD, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
MOELLER, WOLFGANG, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
NITSCHE, DIETRICH, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of bovine colostrum with native proteins obtained
under hygienically clean conditions for the production

of a pharmaceutical preparation for the treatment of
the consequences of disrupted liver function and/or

damage to the hepatic parenchyma in liver disease.
Use according to claim 1, characterised in that the
colostrum is obtained in the first 5 days after

calving.
Use according to claim 1 or 2, characterised in that
the colostrum is obtained in the first 3 days after

calving.
Use according to one of claims 1 to 3, characterised
in that the colostrum is obtained in the first 24

hours after calving.
Use according to one of claims 1 to 4, characterised
in that the colostrum preparation is largely free of

bacteria and toxins.
Use according to one of claims 1 to 5, characterised
in that the colostrum has been defatted.
Use according to one of claims 1 to 6, characterised
in that the colostrum has been defatted and that the

casein has largely been separated.
Use according to claim 7, characterised in that the
colostrum has been defatted, the casein largely

separated and proteins having a molecular weight of
less than 100000 D have largely been separated.
Use according to one of claims 1 to 8, characterised
in that the colostrum preparation is subsequently

sterile-filtered.
</CLAIMS>
</TEXT>
</DOC>
